1. Per cent and timeline of ARV products reviewed by WHO/PQP before and after the USFDA registration.
Per cent and timeline of ARV products reviewed by WHO/PQP before and after the USFDA registration. The graphs indicate the per cent of the applications reviewed and approved by WHO/PQP either before (n=20) or after (n=46) the USFDA registration. Negative months indicate time before the USFDA registration. Panel  (A) shows that of the 20 products, about 45%, 25% and 15% of the products were prequalified 10, 20 and 52 months before the USFDA, respectively. Panel (B) shows that out of the 46 products, 30%, 54% and 87% were approved by WHO at 10, 20 and 30 months after the USFDA registration, respectively. ARV, antiretroviral; PQP, Prequalification of Medicines Programme; USFDA, US Food and Drug Administration.
Harinder Singh Chahal et al. BMJ Glob Health 2018;3:e000651
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) All rights reserved. No commercial use is permitted unless otherwise expressly granted.